As result, we identified five target genes of metformin (RPS6KA5, RORA, SH3BP5, NUPR1, and CD40LG), which were significantly correlated with favorable prognosis and immune infiltration in lung cancer patients. The gene discussed is RORA; the disease is lung carcinoma.